Treatment for spinal muscular atrophy (SMA) type 1 now centers on early use of disease‑modifying drugs (including gene therapy) plus intensive supportive care for breathing, feeding, and movement. The exact plan depends on the baby’s age, genetic results, current strength, and local approval/insurance, so management is usually coordinated by a specialized neuromuscular or SMA clinic.

Main disease‑modifying treatments

These therapies all aim to increase survival motor neuron (SMN) protein or replace the faulty SMN1 gene.

  • Nusinersen (Spinraza®)
    • Antisense oligonucleotide injected into the fluid around the spinal cord (intrathecal).
* Modifies SMN2 splicing to increase SMN protein, and is approved in many regions for infants and children with SMA, including type 1.

* Given as loading doses over the first 2 months, then maintenance doses every 4 months lifelong.
  • Onasemnogene abeparvovec (Zolgensma®) and newer gene therapies (e.g., Itvisma®)
    • One‑time gene‑replacement therapy that delivers a working SMN1 gene via an adeno‑associated virus (AAV) vector.
* Typically given as a single intravenous infusion in symptomatic or pre‑symptomatic children under 2 years (Zolgensma) or as intrathecal gene therapy formulations for some older patients (e.g., Itvisma).

* Long‑term follow‑up shows maintenance of motor milestones for many children treated early.
  • Risdiplam (Evrysdi®)
    • Daily oral small‑molecule that also improves SMN2 splicing to raise SMN protein levels.
* Approved for infants as young as 2 months in many countries and used for SMA types 1–3, often when intrathecal therapy or gene therapy is not suitable.
  • Choice of therapy and combinations
    • Many centers prioritize gene therapy as a one‑time “foundational” treatment in eligible infants, with nusinersen or risdiplam considered in those not eligible or as subsequent therapy depending on evolving evidence and local protocols.
* Early—ideally pre‑symptomatic—treatment after newborn screening leads to markedly better motor outcomes and survival than treatment started later.

Supportive and multidisciplinary care

Even with advanced drugs, babies with SMA type 1 usually need comprehensive supportive care to protect breathing, nutrition, and comfort.

  • Respiratory support
    • Regular monitoring of breathing, cough strength, and sleep studies; early involvement of pulmonology.
* Use of non‑invasive ventilation (e.g., BiPAP), airway clearance devices (cough assist), suction, and vaccinations to prevent infections.
  • Nutrition and feeding
    • Assessment for weak swallowing, risk of aspiration, and poor weight gain.
* Thickened feeds, specialized positioning, or gastrostomy tube (G‑tube) feeding to ensure safe nutrition and medication delivery.
  • Orthopedic and motor management
    • Physiotherapy and occupational therapy to prevent contractures, support sitting or assisted standing, and manage scoliosis.
* Adaptive seating, orthoses, and mobility aids to maximize comfort and participation.
  • Palliative and psychosocial support
    • Honest, ongoing discussions about goals of care, including both life‑prolonging and comfort‑focused options.
* Emotional, social, and financial support for families, often coordinated by SMA foundations or hospital social workers.

“Quick Scoop” style snapshot

  • SMA type 1 is the most severe infant‑onset form, historically leading to early death from respiratory failure, but outcomes are improving with modern therapies.
  • Current frontline treatments include Spinraza (intrathecal), Zolgensma/other SMN1 gene therapies (one‑time infusion or intrathecal), and Evrysdi (oral), all designed to boost or replace SMN.
  • Treatment is time‑critical: babies treated before or soon after symptoms appear have a much higher chance of achieving motor milestones like sitting and, in some cases, walking.
  • Even with these drugs, expert respiratory, nutritional, and rehabilitation care remain essential.

Mini “forum discussion” perspective

“My baby was diagnosed with SMA type 1 from newborn screening—we started gene therapy at 6 weeks and now she can sit and even pull to stand with help. We still have lots of hospital visits for breathing checks and physio, but it’s nothing like what families faced 10 years ago.”

“Our son wasn’t diagnosed until 7 months, so we started nusinersen later. He made gains but still needs BiPAP at night and a feeding tube. Having a coordinated SMA clinic has been crucial; they helped us understand every decision.”

These kinds of real‑world stories reflect what the clinical studies show: earlier treatment and coordinated multidisciplinary care can significantly change the trajectory of SMA type 1, but needs and responses still vary widely child to child.

TL;DR: Treatment for SMA type 1 now combines early SMN‑targeted drugs (Spinraza, Zolgensma/other gene therapies, or Evrysdi) with high‑level respiratory, nutritional, and rehabilitation support in a specialized clinic; starting as early as possible gives the best chance for improved survival and motor function.

Information gathered from public forums or data available on the internet and portrayed here.